Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07656168
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 100 participants
- Registry
-
NCT07656168
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07656168. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2028-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
- Acronym
- PHOENIX
- Condition
- ESRD (End-Stage Renal Disease)
- Condition
- Maintenance Hemodialysis
- Intervention (Device)
- pHA130 Hemoadsorption Cartridge
- Intervention (Device)
- High-flux Hemodialyzer
- Lead sponsor
- China-Japan Friendship Hospital
- Collaborator
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine
Record details
- Record id
cardio:ct-nct07656168- Content hash
b314d31260c7127d2c2e84a6d7a481cbff15c07285d0919c0e06513f8781764c